Daymark Wealth Partners’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Daymark Wealth Partners’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.15M	Buy	+75,910	New	+$3.05M	0.07%	196

Other funds holding FTXH

Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Spire Wealth Management Mclean, Virginia $3.27B AUM 30.11% 1-Year Est. Return

Cyndeo Wealth Partners St. Petersburg, Florida $2.21B AUM 17.29% 1-Year Est. Return

Trust Company of Oklahoma Tulsa, Oklahoma $377M AUM 28.32% 1-Year Est. Return

MinichMacGregor Wealth Management Saratoga Springs, New York $620M AUM 32.35% 1-Year Est. Return

Daymark Wealth Partners's FTXH Position: Q3 2026 in Review

Daymark Wealth Partners opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2026: 75,910 shares worth $3.15M. The stake represents 0.07% of the portfolio and ranks #196 among its holdings.

23 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

Daymark Wealth Partners held 75,910 shares of First Trust Nasdaq Pharmaceuticals ETF worth $3.15M as of Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new Daymark Wealth Partners position in Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF made up 0.07% of Daymark Wealth Partners's portfolio in Q3 2026, its #196 holding.
23 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.